T-cell masthead image

Paper

Paper

“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)

  • External Link
“Visible Light Activated Topical Hypericin Ointment in CTCL: Phase 3 FLASH Study Results” presented by Ellen Kim, MD at the American Academy of Dermatology Virtual Meeting Experience April 24, 2021 (AAD 2021)
Paper

White paper entitled, “SGX301 as a Rapid, Safe and Effective Treatment for Early Stage CTCL,” by Brian Poligone, MD, PhD; Henry Wong, MD, PhD; Aaron Mangold, MD; Jennifer DeSimone, MD; Lucia Seminario-Vidal, MD, PhD; and Ellen Kim, MD, November 13, 2020 (White Paper 2020)

  • External Link
White paper entitled, “SGX301 as a Rapid, Safe and Effective Treatment for Early Stage CTCL,” by Brian Poligone, MD, PhD; Henry Wong, MD, PhD; Aaron Mangold, MD; Jennifer DeSimone, MD; Lucia Seminario-Vidal, MD, PhD; and Ellen Kim, MD, November 13, 2020 (White Paper 2020)
Paper

“Topical Hypericin Ointment (SGX301) Photodynamic Therapy is Effective and Safe in CTCL: Results from the Multicenter Phase 3 FLASH Study” presented by Ellen

  • External Link
“Topical Hypericin Ointment (SGX301) Photodynamic Therapy is Effective and Safe in CTCL: Results from the Multicenter Phase 3 FLASH Study” presented by Ellen
Paper

“Topical Hypericin Ointment Photodynamic Therapy is Effective and Safe in CTCL (FLASH Study)” presented by Ellen Kim, MD at the Society for Investigative Dermatology (SID)Virtual Meeting May 4, 2021 (SID 2021)

  • External Link
“Topical Hypericin Ointment Photodynamic Therapy is Effective and Safe in CTCL (FLASH Study)” presented by Ellen Kim, MD at the Society for Investigative Dermatology (SID)Virtual Meeting May 4, 2021 (SID 2021)
Paper

“Phase 3 Efficacy with a Novel, First in Class, Well-Tolerated Photodynamic Therapy (HyBryte™) for Early Stage Cutaneous T-Cell Lymphoma,” to be presented by Christopher Pullion, DO at the National Organization for Rare Disorders (NORD) Breakthrough Summit, October 18-19, 2021 (NORD 2021)

  • External Link
“Phase 3 Efficacy with a Novel, First in Class, Well-Tolerated Photodynamic Therapy (HyBryte™) for Early Stage Cutaneous T-Cell Lymphoma,” to be presented by Christopher Pullion, DO at the National Organization for Rare Disorders (NORD) Breakthrough Summit, October 18-19, 2021 (NORD 2021)
Paper

“Response in a Patient with Refractory Folliculotropic Mycosis Fungoides to a Topical Hypericin Cream Activated with Fluorescent Light” presented by Brian Poligone, MD, PhD at the 4th World Congress of Cutaneous Lymphomas (WCCL) Congress, February 12-14, 2020 (WCCL 2020)

  • External Link
“Response in a Patient with Refractory Folliculotropic Mycosis Fungoides to a Topical Hypericin Cream Activated with Fluorescent Light” presented by Brian Poligone, MD, PhD at the 4th World Congress of Cutaneous Lymphomas (WCCL) Congress, February 12-14, 2020 (WCCL 2020)
Paper

Vaccine Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection Publication

  • External Link
Albert To, Teri Ann S. Wong, Aquena H. Ball, Michael M. Lieberman, Jake Yalley-Ogunro, Mehtap Cabus, Sara Nezami, Fabian Paz, Hanne Andersen Elyard, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, Courtney Woolsey, Robert W. Cross, Thomas W. Geisbert, Oreola Donini, Axel T. Lehrer,
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection,
Vaccine, 2023, ISSN 0264-410X.
Paper

Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984-90.

  • External Link
Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984-90.